Patents Examined by Robert M. Kelly
  • Patent number: 10434153
    Abstract: Modified T-cells have paratopes against human TK1 epitopes, are made by producing monoclonal antibodies that are specific to TK1, creating chimeric antigen receptors (CARs) by fusion of the single-chain variable fragments (scFv) of the monoclonal antibodies to T-cell signalling domains, and transducing the CARs to the T-cells.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: October 8, 2019
    Inventors: Kim Leslie O'Neill, Scott Weber
  • Patent number: 10434189
    Abstract: A composition for treating cancerous cells in a subject having an immune system includes a virus in the Yatapoxvirus genus having at least one mutation. In one embodiment, the mutation results in suppressed expression of a TNF binding protein by the virus. In another embodiment, the mutation results in suppressed expression of thymidine kinase (“TK”) by the virus. In another embodiment, the mutation arms the virus with a transgene to express a bacterial flagellin. The mutations can be present singly or in combination. Additional aspects include a method of treating cancerous cells with a composition as described herein, and a method of delivering at least one gene to cancerous cells in a subject.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: October 8, 2019
    Assignee: The Board of Trustees of Western Michigan University
    Inventors: Karim Essani, David Jeng, Steven J. Conrad
  • Patent number: 10426753
    Abstract: The present disclosure relates generally to supramolecular combinatorial therapeutics, compositions comprising same, and uses thereof. In particular, the present disclosure provides hydrophobic taxane-lipid covalent conjugates which create supramolecular assembly, for example, within lipid bilayer, providing an extra stabilization resulting in increased intratumoral concentration and hence increased efficacy. The present disclosure also provides supramolecular combinatorial therapeutics, wherein a taxane-lipid conjugate is combined with one or more of a platinum compound, a kinase inhibitor, and an immunoregulator, each of which is optionally conjugated with a lipid.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: October 1, 2019
    Assignee: INVICTUS ONCOLOGY PVT. LTD.
    Inventors: Monideepa Roy, Samad Hossain, Aniruddha Sengupta, Sanghamitra Mylavarapu, Shiladitya Sengupta, Anubhab Mukherjee
  • Patent number: 10413618
    Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: September 17, 2019
    Assignee: Translate Bio, Inc.
    Inventors: Braydon Charles Guild, Frank DeRosa, Michael Heartlein
  • Patent number: 10415017
    Abstract: Described herein are chimeric receptors. Chimeric receptors comprise a cytoplasmic domain; a transmembrane domain; and an extracellular domain. In embodiments, the cytoplasmic domain comprises a cytoplasmic portion of a receptor that when activated polarizes a macrophage. In further embodiments, a wild-type protein comprising the cytoplasmic portion does not comprise the extracellular domain of the chimeric receptor. In embodiments, the binding of a ligand to the extracellular domain of the chimeric receptor activates the intracellular portion of the chimeric receptor. Activation of the intracellular portion of the chimeric receptor may polarize the macrophage into an M1 or M2 macrophage.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: September 17, 2019
    Assignee: Thunder Biotech, Inc.
    Inventor: Kim O'Neill
  • Patent number: 10407476
    Abstract: Disclosed herein are methods and compositions for insertion of transgene sequences encoding proteins involved in clotting into the genome of a cell for treating conditions including hemophilias.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: September 10, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, David Paschon, Edward J. Rebar
  • Patent number: 10390521
    Abstract: This application provides a novel mouse model (PLA2g6 KOEx2) in which genetic deletion of the N terminus of PLA2g6 results in a loss of dopaminergic (DA) neurons in substantia nigra (SN), and development of PD-like motor deficits that can be significantly improved by L-DOPA. Based in part on experimental results demonstrated with this model, this disclosure provides genetically modified animals and genetically modified animal cells that comprise a mutant allele of PLA2g6 and in which store-operated Ca2+ entry (SOCE) is impaired and ER Ca2+ stores are depleted. This disclosure also provides methods of screening a compound for an effect on the SOCE pathway and/or ER Ca2+ by administering the compound to such a genetically modified animal or genetically modified animal cell.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: August 27, 2019
    Assignee: BOSTON MEDICAL CENTER CORPORATION
    Inventor: Victoria Bolotina
  • Patent number: 10391132
    Abstract: The present disclosure relates to recombinant viral vectors for the treatment and prevention of cancer. Oncolytic viral vectors incorporate one or more of the following features: viral replication restriction by insertion of tumor-suppressive microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: August 27, 2019
    Assignee: ONCORUS, INC.
    Inventors: Kenneth P. Greenberg, Mitchell H. Finer
  • Patent number: 10391153
    Abstract: The present invention provides a novel method of treatment for treating brain disorders that manifest oxidative stress by providing targeted populations of neurons with the ability to catabolize the acetylated amino acid derivative, N-acetylaspatic acid (NAA) and further supply extraphysiological levels of ATP to neurons via the targeted expression of the NAA catabolic enzyme aspartoacylase (ASPA) in neurons and astrocytes.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: August 27, 2019
    Assignee: Rowan University
    Inventors: Paola Leone, Jeremy Francis
  • Patent number: 10385336
    Abstract: A Type III-A CRISPR-Cas (StCsm) complex of Streptococcus thermophilus comprising crRNA, Csm4, and Csm3 and use for cleavage of RNA bearing a nucleotide sequence complementary to the crRNA, in vitro or in vivo. Methods for site-specific cleavage/shredding of a target RNA molecule using an RNA-guided RNA endonuclease comprising a minimal complex of crRNA, Csm4, and Csm3, and methods of RNA knock-down and RNA knock-out are disclosed.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: August 20, 2019
    Assignee: VILNIUS UNIVERSITY
    Inventors: Virginijus Siksnys, Migle Kazlauskiene, Gintautas Tamulaitis
  • Patent number: 10377822
    Abstract: Disclosed are a chimeric antigen receptor (CAR) targeting CLD18A2, and preparation method and use thereof. The extracellular binding region of the CAR comprises a protein specifically recognizing CLD18A2. The immune effector cell modified by the CAR can be used to treat tumors such as pancreatic cancer and stomach cancer.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: August 13, 2019
    Assignee: CARsgen Therapeutics LTD.
    Inventors: Huamao Wang, Bo Song, Xiumei Cai
  • Patent number: 10377988
    Abstract: Cells, such a T-cells, are provided that comprise cytokine receptors having increased activity in response to their ligand. For example, cell can comprise IL-2 and/or IL-15 receptors having increased surface expression or signaling activity. Cells of the embodiments have a significant growth advantage in the presence of cytokines and can be used, e.g., for enhanced adoptive cell transfer therapies.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: August 13, 2019
    Assignee: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: Mark Rubinstein, David Cole
  • Patent number: 10369216
    Abstract: The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid molecule and as a preferably non-toxic and non-immunogenic polymeric carrier disulfide-crosslinked cationic components for use as an immunostimulating agent or as an adjuvant, wherein the polymeric carrier cargo complex is administered in combination with at least one second nucleic acid molecule, which encodes a protein or peptide. The inventive polymeric carrier cargo complex administered in combination with the second nucleic acid molecule allows for both efficient transfection of nucleic acids into cells in vivo and in vitro and/or for induction of an innate and/or adaptive immune response, preferably dependent on the nucleic acid to be transported as a cargo and on the second nucleic acid molecule.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: August 6, 2019
    Assignee: CureVac AG
    Inventors: Mariola Fotin-Mleczek, Regina Heidenreich
  • Patent number: 10369232
    Abstract: This invention encompasses compounds, structures, compositions and methods for therapeutic guide molecules that direct CRISPR gene editing. A guide molecule for directing gene editing can be allele selective, or disease allele selective, and can exhibit reduced off target activity. A guide molecule can be composed of monomers, including UNA monomers, nucleic acid monomers, and modified nucleotides, wherein the compound is targeted to a genomic DNA. The guide molecules of this invention can be used as active ingredients for editing or disrupting a gene in vitro, ex vivo, or in vivo.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: August 6, 2019
    Assignee: Arcturus Therapeutics, Inc.
    Inventors: Padmanabh Chivukula, Rachel Wilkie-Grantham, Kiyoshi Tachikawa
  • Patent number: 10370656
    Abstract: Materials and methods for modulating cellular uptake of functionalized nanoparticles are provided. Also provided are materials and methods for modulating the effectiveness of a therapeutic agent with a functionalized nanoparticle.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: August 6, 2019
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Chad A. Mirkin, David A. Giljohann, Dwight S. Seferos
  • Patent number: 10363217
    Abstract: The present invention relates to nano-liposome carrier compositions that encapsulate a hybrid of a Cas9 protein and a guide RNA and methods of making and using the same. The nano-liposome carrier compositions have an excellent effect of suppressing expression of target DNA, and thus pharmaceutical compositions including the nano-liposome carrier compositions can be used for treating diseases such as diabetes.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: July 30, 2019
    Assignee: Moogene Medi Co., Ltd.
    Inventor: Kyeong-Nam Yu
  • Patent number: 10364441
    Abstract: Methods, tip assemblies and kits are provided for introducing material into cells. The tip assemblies include an attachment portion, a channel portion, and a constriction that function to reduce fluid pressure as a fluid passes through the constriction portion from the channel portion, whereby the tip assemblies form pores in the membranes of cells and introduce material into the cells. The material includes for example one selected from the group of: an inorganic compound, a drug, a genetic material, a protein, a carbohydrate, a synthetic polymer, and a pharmaceutical composition.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: July 30, 2019
    Assignee: Tufts University
    Inventor: Thomas J. Diefenbach
  • Patent number: 10350303
    Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: July 16, 2019
    Assignee: Translate Bio, Inc.
    Inventors: Braydon Charles Guild, Frank DeRosa, Michael Heartlein
  • Patent number: 10335456
    Abstract: The present disclosure relates to methods for increasing telomere length in one or more human cells and/or increasing genome stability of one or more human cells, for example by contacting one or more human cells with an agent that increases expression of Zscan4 in the one or more human cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a genomic and/or chromosome abnormality, of rejuvenating one or more human cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 are also provided.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 2, 2019
    Assignee: Elixirgen Therapeutics, Inc.
    Inventor: Minoru S. H. Ko
  • Patent number: 10328109
    Abstract: Described herein is an adenovirus comprising an AB-loop comprising a targeting motif and methods of making and using the adenovirus. The targeting motif of the adenovirus can selectively bind to a tumor cell. The targeting motif of the adenovirus can selectively bind to cell markers and/or cell surface antigens including, for example, CD 133.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: June 25, 2019
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventor: Masato Yamamoto